Genta Targeting Year-End Genasense NDA In Myeloma Or Lymphocytic Leukemia

The NDA will be based on either a 224-patient myeloma study or a 241-patient CLL study. Genta says that it has received helpful feedback from FDA since withdrawing a Genasense NDA for melanoma.